Back to today’s briefing

Story perspectives

FDA Authorizes Abbott Libre Duo, Tracks Glucose and Ketones

8/29/2026

38 6 Full Breakdown

Summary

Abbott Launches Sensor

The U.S. FDA authorized Abbott’s Libre Duo 10-day continuous glucose-ketone sensor.
It is the first U.S. wearable that continuously tracks both glucose and ketones.
Six studies with over 600 participants aged two and older showed accurate ketone tracking for up to ten days.
Hospital admissions for diabetic ketoacidosis have risen 55% over the past decade.
Abbott will launch the sensor this year.

Summary

Abbott Stock Rally

Abbott's stock rallied 9.2% over the past month to $114.10 per share.
Q2 continuous glucose monitor (CGM) sales hit $2.188 billion, a 9.5% comparable increase.
The sales lift underpins earnings guidance of $5.45-$5.60 per share.
Abbott seeks Medicare reimbursement for roughly 10 million Type 2 beneficiaries, which could boost growth.
Integration with insulin-pump makers Beta Bionics and Tandem remains pending, a key commercial hurdle.

1 of 2

Abbott Launches Sensor

The U.S. FDA authorized Abbott’s Libre Duo 10-day continuous glucose-ketone sensor.
It is the first U.S. wearable that continuously tracks both glucose and ketones.
Six studies with over 600 participants aged two and older showed accurate ketone tracking for up to ten days.
Hospital admissions for diabetic ketoacidosis have risen 55% over the past decade.
Abbott will launch the sensor this year.

1 / 2